Gene:
GRIN2D
glutamate receptor, ionotropic, N-methyl D-aspartate 2D

PharmGKB contains no dosing guidelines for this . To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.

PharmGKB contains no drug labels with pharmacogenomic information for this . To report a drug label with PGx, click here.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

This is a non-comprehensive list of genetic tests with pharmacogenetics relevance, typically submitted by the manufacturer and manually curated by PharmGKB. The information listed is provided for educational purposes only and does not constitute an endorsement of any listed test or manufacturer.

A more complete listing of genetic tests is found at the Genetic Testing Registry (GTR).

PGx Test Variants Assayed Related Drugs?

Overview

Alternate Names:  N-methyl-d-aspartate receptor subunit 2D
Alternate Symbols:  EB11; GluN2D; NR2D
PharmGKB Accession Id: PA28982

Details

Cytogenetic Location: chr19 : q13.33 - q13.33
GP mRNA Boundary: chr19 : 48898132 - 48948188
GP Gene Boundary: chr19 : 48888132 - 48951188
Strand: plus
The mRNA boundaries are calculated using the gene's default feature set from NCBI, mapped onto the UCSC Golden Path. PharmGKB sets gene boundaries by expanding the mRNA boundaries by no less than 10,000 bases upstream (5') and 3,000 bases downstream (3') to allow for potential regulatory regions.

Publications related to GRIN2D: 1

No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The consensus coding sequences of human breast and colorectal cancers. Science (New York, N.Y.). 2006. Sjöblom Tobias, et al. PubMed

LinkOuts

Entrez Gene:
2906
OMIM:
602717
UCSC Genome Browser:
NM_000836
RefSeq RNA:
NM_000836
RefSeq Protein:
NP_000827
RefSeq DNA:
AC_000062
AC_000151
NC_000019
NT_011109
NW_001838497
NW_927240
UniProtKB:
NMDE4_HUMAN (O15399)
Q59G17_HUMAN (Q59G17)
Ensembl:
ENSG00000105464
GenAtlas:
GRIN2D
GeneCard:
GRIN2D
MutDB:
GRIN2D
ALFRED:
LO136650V
HuGE:
GRIN2D
Comparative Toxicogenomics Database:
2906
ModBase:
O15399
HumanCyc Gene:
HS02743
HGNC:
4588

Common Searches